A panel of thoracic oncologists have a comprehensive discussion on the treatment of HER2 non–small cell lung cancer, covering diagnosis, therapies, clinical trials, and unmet needs in the treatment space.
EP. 4: DESTINY-Lung01 & DESTINY-Lung02: T-DXd in Metastatic HER2-Mutated NSCLC
April 24th 2024Lyudmila A. Bazhenova, MD, and D. Ross Camidge, MD, PhD, review the DESTINY-Lung01 and DESTINY-Lung02 trials, and the panel provides its impressions of the data.
EP. 6: DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC
May 1st 2024Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2-mutated NSCLC.
EP. 7: Managing Adverse Events Associated With ADCs in HER2-Mutated NSCLC
May 8th 2024Lyudmila A. Bazhenova, MD, an expert on non–small cell lung cancer, provides clinical insights on the management of adverse events associated with antibody-drug conjugates.
EP. 9: Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC
May 15th 2024The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.
EP. 10: First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC
May 15th 2024Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.
IDE397 Shows Early Antitumor Activity, Safety in MTAP-Deletion Urothelial Cancer and NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
2 Commerce Drive
Cranbury, NJ 08512